TNFRSF8

Background

Creative Biolabs provides an extensive selection of top-notch aptamers targeting TNFRSF8 to help researchers improve their experiments and research. Our standards for excellence are upheld, and we are dedicated to supporting your research in biology.

Introduction

TNFRSF8 (TNF Receptor Superfamily Member 8), or CD30, is a member of the tumor necrosis factor receptor family. It is a cell membrane protein as well as a tumor marker. It is a receptor for TNFSF8/CD30L, which regulates cell growth and lymphoblastoid transformation. It activates NF-κB, regulating gene expression. In immune regulation, TNFSF8 is an activation marker of T cells, especially in Th2 cell responses. Activation of TNFSF8 can affect the activation, proliferation, and differentiation of T cells and regulate the direction and intensity of immune responses. Overexpression of TNFSF8 is associated with a variety of occurrences and developments of tumors, especially with specific subtypes. Therefore, TNFSF8 has become an important marker, and immunotherapy strategies targeting TNFSF8 have been widely studied and applied.

The Role in Signaling Pathways

TNFRSF8 plays its role in multiple signaling pathways that provide a survival advantage to cells with upregulated TNFRSF8. When stimulated, TNFRSF8 recruits TNFR-associated factors (TRAFs) and TRAF-binding proteins, leading to receptor trimerization and the generation of a signaling complex that promotes the NF-κB pathway. The signaling process has been linked to TRAF2, TRAF1, and TRAF5. In addition, TNFRSF8 participates in mitogen-activated protein kinase (MAPK) signaling pathways that play multiple anti-apoptotic and pro-survival roles in tumor cells.

Fig.1 TNFRSF8/CD30-mediated signaling pathway.¹

TNFRSF8 as a Therapeutic Target

Specific lymphoma subtypes and some non-lymphoid tumors show overexpression of TNFRSF8, indicating its potential as a therapeutic target. Monoclonal antibodies (mAbs) targeting surface receptors have emerged as a new and valuable treatment option for many hematological malignancies. TNFRSF8 is a promising target for treating Hodgkin lymphoma and ALK⁺ anaplastic large cell lymphoma due to its limited presence on normal activated lymphocytes and higher presence on malignant cells. Additionally, varying levels of TNFRSF8 expression are observed in peripheral T-cell lymphoma, extranodal NKT-cell lymphoma, cutaneous T-cell lymphoma, diffuse large B-cell lymphoma, and certain cases of systemic mastocytosis. In addition to being used for diagnosis, TNFRSF8 helps determine the progression of diffuse large B-cell lymphoma and enormous cell transformation of cutaneous T-cell lymphoma. Infiltration of TNFRSF8-positive cells may also occur in reactive lesions, including but not limited to the following diseases: infections (milkman's nodule virus, herpes simplex virus, varicella-zoster virus, molluscum contagiosum, scabies, leishmaniasis, syphilis), inflammations (lymphoma-like drug reaction, frostbite), ruptured cysts, and re-excision of tumors.

TNFRSF8 Aptamer Analysis

Creative Biolabs provides a wide range of TNFRSF8 related products, including anti-streptavidin aptamer. Our products can effectively help you conduct experiments and play an important role in your research.

Fig 2. Nanocomplex targeting ALCL cells with CD30 aptamer and siRNA.²

One potential therapeutic approach to halt tumor growth is silencing oncogenes via siRNA, but its limitation is that it is not cell-type selective and therefore cannot specifically target tumor cells. Nianxi Zhao et al. investigated a functional RNA nanocomplex that combines TNFRSF8/CD30 ligand and anaplastic lymphoma kinase (ALK) siRNA to specifically target human anaplastic large cell lymphoma (ALCL).² CD30 is a unique surface biomarker in lymphoma cells. The integration of the CD30 aptamer facilitates the accumulation of the nanocomplex within specific tumor sites. In addition, the bound CD30 aptamer was able to eliminate potential off-target side effects of the nanocomplex components.

Creative Biolabs provides various TNFRSF8 products to fulfill your diverse experimental requirements.

References

1. Dumitru, Adrian Vasile, et al. "The polyvalent role of CD30 for cancer diagnosis and treatment." Cells 12.13 (2023): 1783. Distributed under Open Access license CC BY 4.0, without modification.
2. Zhao, Nianxi, et al. "A nanocomplex that is both tumor cell-selective and cancer gene-specific for anaplastic large cell lymphoma." Journal of Nanobiotechnology 9 (2011): 1-12. Distributed under Open Access license CC BY 2.0, without modification.